Controversy in the management of retinal venous occlusive disease

International Ophthalmology Clinics

Volumn 44, Issue 4, 2004, Pages 85-102

  Bearelly, Srilaxmi ^a   Fekrat, Sharon ^a  

^a DUKE UNIVERSITY EYE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTICOAGULANT AGENT; CORTICOSTEROID; FLUOCINOLONE ACETONIDE; HEPARIN; IMMUNOSUPPRESSIVE AGENT; PENTOXIFYLLINE; TRIAMCINOLONE ACETONIDE; WARFARIN;

ANTICOAGULANT THERAPY; ARTERIOVENOUS SHEATHOTOMY; BRAIN HEMORRHAGE; BRANCH RETINA VEIN OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; CHORIORETINAL VENOUS ANASTOMOSIS; CILIARY DISK; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DECOMPRESSION SURGERY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; GRID LASER COAGULATION; HEMATOLOGIC DISEASE; HEMIRETINAL VEIN OCCLUSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAOCULAR HYPERTENSION; LASER COAGULATION; LOW DRUG DOSE; NONHUMAN; OPEN ANGLE GLAUCOMA; PARS PLANA VITRECTOMY; PRIORITY JOURNAL; RADIAL OPTIC NEUROTOMY; RETINA MACULA EDEMA; RETINA NEOVASCULARIZATION; RETINA VEIN OCCLUSION; REVIEW; RISK FACTOR; SURGICAL TECHNIQUE; VEIN ANASTOMOSIS; VISUAL IMPAIRMENT; VITRECTOMY; VITREOUS HEMORRHAGE;

CONNECTIVE TISSUE; DECOMPRESSION, SURGICAL; GLUCOCORTICOIDS; HUMANS; LASER COAGULATION; PRACTICE GUIDELINES; RETINAL VEIN OCCLUSION; RISK FACTORS; VITRECTOMY;

EID: 6344272219     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004397-200404440-00008     Document Type: Review

References (98)

1. David R, Zangwill L, Badarna M, et al. Epidemiology of retinal vein occlusion and its association with glaucoma and increased intraocular pressure. Ophthalmologica. 1988;197:69.
2. Klein R, Klein BE, Moss SE, et al. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc. 2000;98:133.
3. Branch Vein Occlusion Study Group. Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Arch Ophthalmol. 1986;104:34.
4. Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol. 1984;98:271.
5. The Central Vein Occlusion Study Group. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion: the Central Vein Occlusion Study Group N report. Ophthalmology. 1995;102:1434.
6. The Central Vein Occlusion Study Group. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. Ophthalmology. 1995;102:1425.
7. The Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group. Arch Ophthalmol. 1997;115:486.
8. Cooney MJ, Fekrat S, Finkelstein D. Current concepts in the management of central retinal vein occlusion. Curr Opin Ophthalmol. 1998;9:47.
9. Fekrat S, Finkelstein D. Venous occlusive disease. In: Regillo CD, Brown GC, Flynn HW, eds. Vitreoretinal Disease: The Essentials. New York, NY: Thieme; 1999:117.
10. Fekrat S, Finkelstein D. Branch retinal vein occlusion. In: Schachat AP, ed. Retina. 3rd ed. St. Louis, MO: Mosby; 2001:1376.
11. Zhao J, Sastry SM, Sperduto RD, et al. Arteriovenous crossing patterns in branch retinal vein occlusion: The Eye Disease Case-Control Study Group. Ophthalmology. 1993;100:423-428.
12. Weinberg D, Dodwell DG, Fern SA. Anatomy of arteriovenous crossings in branch retinal vein occlusion. Am J Ophthalmol. 1990;109:298-302.
13. Duker JS, Brown GC. Anterior location of the crossing artery in branch retinal vein obstruction. Arch Ophthalmol. 1989;107:998-1000.
14. Seitz R. The Retinal Vessels. St. Louis, MO: CV Mosby; 1964:20-74.
15. Ariturk N, Oge Y, Erkan D, et al. Relation between retinal vein occlusions and axial length. Br J Ophthalmol. 1996;80:633-636.
16. Majji AB, Janarthanan M, Naduvilath TJ. Significance of refractive status in branch retinal vein occlusion: a case-control study. Retina. 1997;17:200-204.
17. Simons BD, Brucker AJ. Branch retinal vein occlusion: axial length and other risk factors. Retina. 1997;17:191-195.
18. Timmerman EA, de Lavalette VW, van den Brom HJ. Axial length as a risk factor to branch retinal vein occlusion. Retina. 1997;17:196-199.
19. Kumar B, Yu DY, Morgan WH, et al. The distribution of angioarchitectural changes within the vicinity of the arteriovenous crossing in branch retinal vein occlusion. Ophthalmology. 1998;105:424-427.
20. Clemett RS. Retinal branch vein occlusion: changes at the site of obstruction. Br J Ophthalmol. 1974;58:548-554.
21. Bowers DK, Finkelstein D, Wolff SM, et al. Branch retinal vein occlusion: a clinicopathological case report. Retina. 1987;7:252-259.
22. Eye Disease Case-Control Study Group. Risk factors for branch retinal vein occlusion. Am J Ophthalmol. 1993;116:286-296.
23. Lahey JM, Tunc M, Kearney J, et al. Laboratory evaluation of hypercoagulable states in patients with central retinal vein occlusion who are less than 56 years of age. Ophthalmology. 2002;109:126-131.
24. Lahey JM, Kearney JJ, Tunc M. Hypercoagulable states and central retinal vein occlusion. Curr Opin Pulm Med. 2003;9:385-392.
25. Cahill MT, Stinnett SS, Fekrat S. Meta-analysis of plasma homocysteine, serum folate, serum vitamin B12, and thermolabile MTHFR genotype as risk factors for retinal vascular occlusive disease. Am J Ophthalmol. 2003;136:1136-1150.
26. Fekrat S, Finkelstein D. In: Regillo CD, Brown GC, Flynn HW, eds. Vitreoretinal Disease: The Essentials. New York, NY: Thieme; 1999:117.
27. Finkelstein D. Ischemic macular edema: recognition and favorable natural history in branch vein occlusion. Arch Ophthalmol. 1992;110:1427-1434.
28. Finkelstein D. Laser treatment of macular edema resulting from branch vein occlusion. Semin Ophthalmol. 1994;9:23.
29. Wilson DJ, Finkelstein D, Quigley HA, et al. Macular grid photocoagulation. An experimental study on the primate retina. Arch Ophthalmol. 1988;106:100.
30. Takahashi M, Hikichi T, Akiba J, et al. Role of the vitreous and macular edema in branch retinal vein occlusion. Ophthalmic Surg Lasers. 1997;28:294-299.
31. Saika S, Tanaka T, Miyamoto T. Surgical posterior vitreous detachment combined with gas/air tamponade for treating macular edema associated with branch retinal vein occlusion: retinal tomography and visual outcome. Graefes Arch Clin Exp Ophthalmol. 2001;239:729.
32. Amirikia A, Scott IU, Murray TG, et al. Outcomes of vitreoretinal surgery for complications of branch retinal vein occlusion. Ophthalmology. 2001;108:372.
33. Kurimoto M, Takagi H, Suzuma K. Vitrectomy for macular edema secondary to retinal vein occlusion: evaluation by retinal thickness analyzer. Jpn J Ophthalmol. 1999;53:717.
34. Ando N. Vitrectomy for ischemic maculopathy associated with retinal vein occlusion. Presented at: Vail Vitrectomy Meeting; 2000; Vail.
35. Shah GK. Adventitial sheathotomy for treatment of macular edema associated with branch retinal vein occlusion. Curr Opin Ophthalmol. 2000;11:171.
36. Osterloh MD, Charles S. Surgical decompression of branch retinal vein occlusions. Arch Ophthalmol. 1988;106:1469.
37. Mester U, Dillinger P. Vitrectomy with decompression in branch retinal vein occlusion. Presented at: Club Jules Gonin Meeting; 2000; Sicily, Italy.
38. Opremcak EM, Bruce RA. Surgical decompression of branch retinal vein occlusion via arteriovenous crossing sheathotomy: a prospective review of 15 cases. Retina. 1999;19:1.
39. Shah GK, Sharma S, Fineman MS, et al. Arteriovenous adventitial sheathotomy for the treatment of macular edema associated with branch retinal vein occlusion. Am J Ophthalmol. 2000;129:104.
40. Han DP, Bennett SR, Williams DF, et al. Arteriovenous crossing dissection without separation of the retina vessels for treatment of branch retinal vein occlusion. Retina. 2003;23:145-151.
41. Cahill MT, Fekrat S. Arteriovenous sheathotomy for branch retinal vein occlusion. Ophthalmol Clin North Am. 2002;15:417-423.
42. Martidis A, Duker JS, Greenberg P, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002;109:920-927.
43. Park CH, Jaffe GJ, Fekrat S. Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. Am J Ophthalmol. 2003;136:419-425.
44. Greenberg PB, Martidis A, Rogers AH, et al. Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Br J Ophthalmol. 2002;86:247-248.
45. Ip MS, Kumar KS. Intravitreous triamcinolone acetonide as treatment for macular edema from central retinal vein occlusion. Arch Ophthalmol. 2002;120:1217-1219.
46. Wilson CA, Berkowitz BA, Sato Y, et al. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol. 1992;110:1155-1159.
47. McCuen BW, Bessler M, Tano Y, et al. The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol. 1981;91:785-788.
48. Hida T, Chandler D, Arena J, et al. Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol. 1986;101:190-195.
49. Schindler R, Chandler D, Thresher R, et al. The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol. 1982;93:415-417.
50. Beer PM, Bakri SJ, Singh RJ, et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003;110:681-686.
51. Sperduto RD, Hiller R, Chew E, et al. Risk factors for hemiretinal vein occlusion: comparison with risk factors for central and branch retinal vein occlusion: The Eye Disease Case-Control Study. Ophthalmology. 1998;105:765.
52. Hayreh SS, Hayreh MS. Hemi-central retinal vein occlusion: pathogenesis, clinical features, and natural history. Arch Ophthalmol. 1980;98:1600.
53. Appiah AP, Trempe CL. Differences in contributory factors among hemicentral, central, and branch retinal vein occlusions. Ophthalmology. 1989;96:364.
54. Chopdar A. Dual trunk central retinal vein incidence in clinical practice. Arch Ophthalmol. 1984;102:85.
55. Clarkson JG. Central retinal vein occlusion. In: Schachat AP, ed. Retina. 3rd ed. St. Louis, MO: Mosby; 2001:1368.
56. The Eye Disease Case-Control Study Group. Risk factors for central retinal vein occlusion. Arch Ophthalmol. 1996;114:545.
57. Green W, Chan C, Hutchins G, et al. Central retinal vein occlusions: a prospective histopathologic study of 29 eyes in 28 cases. Trans Am Ophthalmol Soc. 1981;79:371-422.
58. Browning DJ, Scott AQ, Peterson CB, et al. The risk of missing angle neovascularization by omitting screening gonioscopy in acute central retinal vein occlusion. Ophthalmology. 1998;105:776-784.
59. The Central Vein Occlusion Study Group. Baseline and early natural history report. The Central Vein Occlusion Study. Arch Ophthalmol. 1993;111:1087.
60. Gutman FA. Evaluation of a patient with central retinal vein occlusion. Ophthalmology. 1983;90:481-483.
61. Fong AC, Schatz H. Central retinal vein occlusion in young adults. Surv Ophthalmol. 1993;38:88.
62. Williamson TH, Rumley A, Lowe GD. Blood viscosity, coagulation, and activated protein C resistance in central retinal vein occlusion: a population controlled study. Br J Ophthalmol. 1996;80:203-208.
63. Abu El-Asrar AM, Abdel Gader AG, Al-Amro S, et al. Hypercoagulable states in patients with retinal venous occlusion. Doc Ophthalmol. 1998;95:133-143.
64. Hayreh SS, Zimmerman MB, Podhajsky P. Hematologic abnormalities associated with various types of retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2002;240:180-196.
65. Gottlieb JL, Blice JP, Mestichelli B, et al. Activated protein C resistance, factor V Leiden, and central retinal vein occlusion in young adults. Arch Ophthalmol. 1998;116:577-579.
66. Hvarfner C, Hillarp A, Larsson J. Influence of factor V Leiden on the development of neovascularisation secondary to central retinal vein occlusion. Br J Ophthalmol. 2003;87:305-306.
67. Ciardella AP, Clarkson JG, Guyer DR, et al. Central retinal vein occlusion: a primer and review. In: Guyer DR, Yannuzzi LA, Chang S, ed. Retina-Vitreous-macula. New York, NY: W.B. Saunders; 1999.
68. Francis PJ, Stanford MR, Graham EM. Dehydration is a risk factor for central retinal vein occlusion in young patients. Acta Ophthalmol Scand. 2003;81:415-416.
69. Rumelt S, Karatas M, Pikkel J, et al. Optic disc traction syndrome associated with central retinal vein occlusion. Arch Ophthalmol. 2003;121:1093-1097.
70. Group TCVOS. Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group. Arch Ophthalmol. 1997;115:486-491.
71. Lai JC, Mruthyunjaya P, Fekrat S. Central retinal vein occlusion in patients on chronic Coumadin® anticoagulation. Invest Ophthalmol Vis Sci. 2002;42:ARVO E.
72. De Sanctis MT, Cesarone MR, Belcaro G, et al. Treatment of retinal vein thrombosis with pentoxifylline: a controlled, randomized trial. Angiology 2002;53(suppl 1):S35-S38.
73. Wolf S, Arend O, Bertram B, et al. Hemodilution therapy in central retinal vein occlusion. One-year results of a prospective randomized study. Graefes Arch Clin Exp Ophthalmol. 1994;232:33-39.
74. Shaikh S, Blumenkranz MS. Transient improvement in visual acuity and macular edema in central retinal vein occlusion accompanied by inflammatory features after pulse steroid and anti-inflammatory therapy. Retina. 2001;21:176-178.
75. Fekrat S, de Juan E Jr. Chorioretinal venous anastomosis for central retinal vein occlusion: transvitreal venipuncture. Ophthalmol Surg Lasers. 1999;30:52-55.
76. Fekrat S, Goldberg MF, Finkelstein D. Laser-induced chorioretinal venous anastomosis for nonischemic central or branch retinal vein occlusion. Arch Ophthalmol. 1998;116:43-52.
77. Browning DJ, Antoszyk AN. Laser chorioretinal venous anastomosis for nonischemic central retinal vein occlusion. Ophthalmology. 1998;105:670-677, discussion 677-679.
78. McAllister IL, Constable IJ. Laser-induced chorioretinal venous anastomosis for treatment of nonischemic central retinal vein occlusion. Arch Ophthalmol. 1995;113:456-462.
79. McAllister IL, Douglas JP, Constable IJ, et al. Laser-induced chorioretinal venous anastomosis for nonischemic central retinal vein occlusion: evaluation of the complications and their risk factors. Am J Ophthalmol. 1998;126:219-229.
80. Browning D, Rotberg M. Vitreous hemorrhage complicating laser-induced chorioretinal anastomosis for central retinal vein occlusion. Am J Ophthalmol. 1996;122:588-589.
81. Kwok AK, Lee VY, Lai TY, et al. Laser induced chorioretinal venous anastomosis in ischaemic central retinal vein occlusion. Br J Ophthalmol. 2003;87:1043-1044.
82. Lam HD, Blumenkranz MS. Treatment of central retinal vein occlusion by vitrectomy with lysis of vitreopapillary and epipapillary adhesions, subretinal peripapillary tissue plasminogen activator injection, and photocoagulation. Am J Ophthalmol. 2002;134:609-611.
83. Yeshaya A, Treister G. Pars plana vitrectomy for vitreous hemorrhage and retinal vein occlusion. Ann Ophthalmol. 1983;15:615-617.
84. Opremcak EM, Bruce RA, Lomeo MD, et al. Radial optic neurotomy for central retinal vein occlusion: A retrospective pilot study of 11 consecutive cases. Retina. 2001;21:408-415.
85. Dev S, Buckley EG. Optic nerve sheath decompression for progressive central retinal vein occlusion. Ophthalmol Surg Lasers. 1999;30:181-184.
86. Vasco-Posada J. Modification of the circulation in the posterior pole of the eye. Ann Ophthalmol. 1972;4:48-59.
87. Weizer JS, Stinnett SS, Fekrat S. Radial optic neurotomy as treatment for central retinal vein occlusion. Am J Ophthalmol. 2003;136:814-819.
88. Garcia-Arumi J, Boixadera A, Martinez-Castillo V, et al. Chorioretinal anastomosis after radial optic neurotomy for central retinal vein occlusion. Arch Ophthalmol. 2003;121:1385-1391.
89. Hattenbach LO, Steinkamp G, Scharrer I, et al. Fibrinolytic therapy with low-dose recombinant tissue plasminogen activator in retinal vein occlusion. Ophthalmologica. 1998;212:394-398.
90. Hattenbach LO, Wellermann G, Steinkamp GW, et al. Visual outcome after treatment with low-dose recombinant tissue plasminogen activator or hemodilution in ischemic central retinal vein occlusion. Ophthalmologica. 1999;213:360-366.
91. Lahey JM, Fong DS, Kearney J. Intravitreal tissue plasminogen activator for acute central retinal vein occlusion. Ophthalmol Surg Lasers. 1999;30:427-434.
92. Glacet-Bernard A, Kuhn D, Vine AK, et al. Treatment of recent onset central retinal vein occlusion with intravitreal tissue plasminogen activator: a pilot study. Br J Ophthalmol. 2000;84:609-613.
93. Elman MJ, Raden RZ, Carrigan A. Intravitreal injection of tissue plasminogen activator for central retinal vein occlusion. Trans Am Ophthalmol Soc. 2001;99:219-221, discussion 222-223.
94. Ghazi NG, Noureddine BN, Haddad RS, et al. Intravitreal tissue plasminogen activator in the management of central retinal vein occlusion. Retina. 2003;23:780-784.
95. Weiss JN. Treatment of central retinal vein occlusion by injection of tissue plasminogen activator into a retinal vein. Am J Ophthalmol. 1998;126:142-144.
96. Paques M, Vallee JN, Herbreteau D, et al. Superselective ophthalmic artery fibrinolytic therapy for the treatment of central retinal vein occlusion. Br J Ophthalmol. 2000;84:1387-1391.
97. Weiss JN, Bynoe LA. Injection of tissue plasminogen activator into a branch retinal vein in eyes with central retinal vein occlusion. Ophthalmology. 2001;108:2249-2257.
98. Bynoe LA, Weiss JN. Retinal endovascular surgery and intravitreal triamcinolone acetonide for central vein occlusion in young adults. Am J Ophthalmol. 2003;135:382-384.